Tirzepatide 30mg

RetaLABS Tirzepatide 30mg is a lyophilised research vial of LY3298176, a dual GLP-1 and GIP receptor agonist developed by Eli Lilly, the first compound in the "twincretin" class. The 30mg vial aligns directly with the SURMOUNT-1 maximum dose of 15mg/week, providing two weeks of research supply at peak dose, or up to twelve weeks at the 2.5mg/week escalation starting point. The 30mg format is the best-value choice for Australian researchers running the full SURMOUNT-style escalation schedule from 2.5mg through 15mg.

Supplied as a white lyophilised powder. Shipped via Express Post Australia-wide in discrete, unmarked packaging, typically dispatched within 1–2 business days of confirmed crypto payment (BTC, LTC, or XMR).

Why Tirzepatide Is Mechanistically Distinct

Tirzepatide was the first dual incretin receptor agonist to reach human clinical use, engaging two of the body's three primary metabolic receptors simultaneously:

• GLP-1R (Glucagon-Like Peptide-1 Receptor). Drives glucose-dependent insulin secretion, suppresses glucagon, slows gastric emptying, and signals satiety via hypothalamic and brainstem pathways. This is the receptor engaged by Semaglutide as a single target.
• GIPR (Glucose-dependent Insulinotropic Polypeptide Receptor). Amplifies beta-cell insulin secretion through pathways distinct from GLP-1R, modulates adipose tissue lipid handling, and appears to dampen the GI adverse-event signal that GLP-1R agonism alone produces. Adding GIPR is the central design innovation that produced Tirzepatide's superior SURMOUNT-1 outcomes versus Semaglutide STEP 1.

For the GIP receptor entity overview including the historical receptor-biology context, see GIP Receptor Explained. For GLP-1 itself see GLP-1 Explained. The third receptor target, Glucagon Receptor (GcgR), is engaged only by Retatrutide; Tirzepatide does not bind GcgR.

SURMOUNT Trial Data, What Researchers Are Working From

The pivotal SURMOUNT-1 trial (Jastreboff et al., NEJM 2022, NCT04184622) enrolled 2,539 adults with obesity (no type 2 diabetes) over 72 weeks. Top-line outcomes at the 72-week primary endpoint, by dose:

Dose cohort	Mean weight loss	≥5% loss responders
Placebo	3.1%	~35%
5mg/week	15.0%	~85%
10mg/week	19.5%	~89%
15mg/week	20.9%	~91%

Additional SURMOUNT programme results: SURMOUNT-2 (adults with T2D, 72 weeks) reported 15.7% mean loss at 15mg; SURMOUNT-3 (intensive lifestyle lead-in, 72 weeks) reached 26.6% total loss from original baseline; SURMOUNT-4 (maintenance) showed continuation-group maintaining 21.8% total loss while withdrawal-group regained to 9.9% by week 88, the discontinuation pattern that mirrors the STEP 4 Semaglutide finding and implies sustained receptor engagement is required for sustained outcomes.

The 30mg vial covers the SURMOUNT escalation cleanly: 2.5 + 2.5 + 2.5 + 2.5 + 5 + 5 + 5 + 5 + 7.5 + 7.5 + 7.5 + 7.5 + 10 + 10 + 10 + 10 = 105 mg over 20 weeks to reach the 15mg maintenance dose. Two 30mg vials cover the full escalation; subsequent maintenance can be planned around a 30mg-vial cadence (2 weeks of supply per vial at 15mg/week).

For full SURMOUNT-1 through SURMOUNT-4 analysis see the Tirzepatide SURMOUNT Trial Deep Dive. For SURPASS (T2D outcomes), see the Tirzepatide Research Guide.

Cross-Compound Comparison

Tirzepatide research sits in the middle of the GLP-1 class (between single-receptor Semaglutide and triple-receptor Retatrutide. The following table is cross-trial (different populations, durations, dose designs) not head-to-head) and so direct ranking requires caution:

Metric	Semaglutide	Tirzepatide	Retatrutide
Receptor targets	GLP-1R	GLP-1R + GIPR	GLP-1R + GIPR + GcgR
Compound class	Single	Dual (twincretin)	Triple agonist
Developer	Novo Nordisk	Eli Lilly	Eli Lilly
Pivotal trial	STEP 1, 68 weeks	SURMOUNT-1, 72 weeks	Phase 2, 48 weeks
Trial enrolment	1,961	2,539	338
Highest dose	2.4mg/week	15mg/week	12mg/week
Mean weight loss (highest dose)	14.9%	20.9%	24.2%
Half-life	~7 days	~5 days	~6 days
Phase 3 status	Complete	Complete	TRIUMPH ongoing

For full side-by-side comparisons see Retatrutide vs Tirzepatide and the GLP-1 Peptides Comparison Guide.

Reconstitution at a Glance

The most common research-protocol approach for a 30mg Tirzepatide vial: add 3.0mL bacteriostatic water to produce a 10mg/mL working concentration. At this concentration, individual dose volumes on a standard U100 insulin syringe are:

Dose (SURMOUNT)	Volume at 10mg/mL	U100 syringe units	Doses per vial
2.5 mg (start)	0.25 mL	25 units	12
5 mg	0.50 mL	50 units	6
7.5 mg	0.75 mL	75 units	4
10 mg	1.00 mL	100 units	3
15 mg (peak)	1.50 mL	150 units (split inj.)	2

At 15mg dose volumes (1.5 mL), researchers commonly split the injection across two sites at the same session for tolerability. Reconstitution technique: inject the bacteriostatic water slowly down the inner wall of the vial, swirl gently (do not shake), and store the reconstituted solution refrigerated at 2–8°C. The bacteriostatic water diluent contains 0.9% benzyl alcohol as a preservative, supporting multiple withdrawals from the same vial across an approximately 4-week stability window. For full protocol detail see the Peptide Reconstitution & Storage Guide and the reconstitution calculator.

Sourcing, Quality & Documentation

RetaLABS Tirzepatide is supplied as research-grade, manufacturer-verified lyophilised peptide. Each batch is purity-tested by HPLC. Where a batch is published, its Certificate of Analysis appears on this page; full batch documentation is available on request, email support@retalabs.is with your order number.

All Tirzepatide vials are supplied for laboratory research use only. Tirzepatide has approved therapeutic registrations in the United States and other jurisdictions under different product brand names; the research-grade material supplied by RetaLABS is sold through a separate channel and is not the same product as approved therapeutic versions. By placing an order you confirm the compound is acquired for research purposes and not for human consumption.

Primary Research References

The core peer-reviewed publications underlying current Tirzepatide research:

• Jastreboff AM et al. "Tirzepatide Once Weekly for the Treatment of Obesity." New England Journal of Medicine, 2022; 387:205-216. doi:10.1056/NEJMoa2206038. The pivotal SURMOUNT-1 trial in adults with obesity (no T2D). NCT04184622.
• Garvey WT et al. "Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial." The Lancet, 2023; 402:613-626. SURMOUNT-2 in adults with T2D. NCT04657003.
• Wadden TA et al. "Tirzepatide after intensive lifestyle intervention in adults with overweight or obesity: the SURMOUNT-3 phase 3 trial." Nature Medicine, 2023; 29:2909-2918. SURMOUNT-3 intensive lifestyle lead-in. NCT04657016.
• Aronne LJ et al. "Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial." JAMA, 2024; 331:38-48. SURMOUNT-4 maintenance trial. NCT04660643.
• Coskun T et al. "LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept." Molecular Metabolism, 2018; 18:3-14. Original receptor-binding characterisation and Phase 1 pharmacokinetic profile.
• ClinicalTrials.gov registrations: SURMOUNT-1 NCT04184622, SURMOUNT-2 NCT04657003, SURMOUNT-3 NCT04657016, SURMOUNT-4 NCT04660643, SURMOUNT-MMO (cardiovascular outcomes) NCT05556512.

The RetaLABS Research Team's editorial and sourcing methodology is documented at the RetaLABS Research Team profile.

Related Research Reading

• Tirzepatide Research Guide, full mechanism, SURMOUNT + SURPASS data, reconstitution, sourcing
• SURMOUNT Trial Deep Dive, all four SURMOUNT trials analysed in depth
• Dosing Protocol Reference, SURMOUNT escalation schedule + reconstitution maths
• Retatrutide vs Tirzepatide, dual vs triple agonist research comparison
• GLP-1 Peptides Comparison Guide, Semaglutide vs Tirzepatide vs Retatrutide
• GIP Receptor Explained, the second receptor that distinguishes Tirzepatide from Semaglutide